Mesoblast Limited vs Target Corporation — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Target Corporation trades at $138.64 (market cap $63.40B). The key difference: Target Corporation is far larger — about 29.2× Mesoblast Limited's market cap, and Target Corporation pays a 3.32% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TGT | |
|---|---|---|
Market Cap | $2.17B | $63.40B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $141.19 |
52-Week Low | $12.88 | $83.68 |
Enterprise Value | $2.17B | $78.70B |
Dividend Yield | — | 3.32% |
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →